BNP PARIBAS ASSET MANAGEMENT Holding S.A. Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 125,898 shares of the company's stock, valued at approximately $5,665,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.21% of Protagonist Therapeutics at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Millennium Management LLC raised its position in Protagonist Therapeutics by 2,135.6% in the second quarter. Millennium Management LLC now owns 958,283 shares of the company's stock worth $33,205,000 after acquiring an additional 915,418 shares in the last quarter. Perceptive Advisors LLC raised its position in Protagonist Therapeutics by 27.6% in the second quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company's stock worth $43,962,000 after acquiring an additional 274,412 shares in the last quarter. Renaissance Technologies LLC raised its position in Protagonist Therapeutics by 813.4% in the second quarter. Renaissance Technologies LLC now owns 297,467 shares of the company's stock worth $10,307,000 after acquiring an additional 264,900 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Protagonist Therapeutics in the second quarter worth $5,467,000. Finally, Victory Capital Management Inc. increased its position in shares of Protagonist Therapeutics by 1,729.3% in the third quarter. Victory Capital Management Inc. now owns 130,797 shares of the company's stock valued at $5,886,000 after buying an additional 123,647 shares in the last quarter. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Stock Down 2.0 %

Shares of PTGX traded down $0.93 during trading hours on Monday, reaching $45.53. 1,324,520 shares of the company traded hands, compared to its average volume of 751,650. The stock has a market capitalization of $2.71 billion, a PE ratio of 17.12 and a beta of 2.17. Protagonist Therapeutics, Inc. has a fifty-two week low of $16.80 and a fifty-two week high of $48.89. The stock has a fifty day simple moving average of $45.24 and a 200 day simple moving average of $39.47.

Insider Activity

In related news, insider Arturo Md Molina sold 1,906 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the sale, the insider now directly owns 46,444 shares in the company, valued at approximately $1,903,275.12. This trade represents a 3.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William D. Waddill sold 8,000 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the sale, the director now owns 12,000 shares in the company, valued at approximately $540,000. The trade was a 40.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,109 shares of company stock valued at $1,069,999 in the last three months. Corporate insiders own 5.40% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. JMP Securities dropped their price target on Protagonist Therapeutics from $45.00 to $43.00 and set a "market outperform" rating for the company in a research report on Wednesday, August 7th. Wedbush restated an "outperform" rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. StockNews.com upgraded Protagonist Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Finally, TD Cowen upgraded Protagonist Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 25th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $53.57.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.